August 23, 2024 06:45 AM EDTUpdated 07:23 AM
Startups
Cell/Gene Tx

Gene in­ser­tion start­up Tome Bio­sciences stops lab work as CEO shifts fo­cus to deal talks

Ryan Cross

Senior Science Correspondent

Tome Bio­sciences, a high-pro­file gene edit­ing start­up spun out of MIT, is halt­ing its lab work and look­ing to sell it­self or find a part­ner …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times